Characteristics of patients with diffuse large B-cell lymphoma of gastrointestinal tract: A single center experience

Abstract

Objectives: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with approximately one-third of patients presenting with extranodal involvement. The gastrointestinal (GI) tract is the most commonly affected extranodal site. This retrospective study aimed to evaluate the clinical characteristics and treatment outcomes of patients diagnosed with GI-DLBCL at a tertiary care hospital between 2015 and 2024. Patients and Methods: Data of patients diagnosed with GI-DLBCL were retrospectively collected from electronic medical records. Patients with lymphoma subtypes other than DLBCL were excluded from the study. Results: A total of 35 patients were included. The median age at diagnosis was 57 years, and 48.6% were male. The most frequent histologic subtype was “DLBCL, not otherwise specified (NOS)”. The stomach was the most common site of extranodal involvement. Two-thirds of the patients presented with advanced-stage disease. Rituximab-based therapies including cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab (R-CHOP) were administered as first-line treatment in 82.9% of patients, and a complete response was achieved in 71.4%. At a median follow-up of 45 months, median progression-free survival and overall survival had not yet been reached. Conclusion: Despite a high rate of advanced-stage disease, R-CHOP treatment achieved high response rates and durable survival. Molecular profiling may help better understand the biological heterogeneity of GI-DLBCL.

Keywords

• Gastrointestinal tract
• Diffuse large B cell lymphoma
• Prognosis

References

1. Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol 2025;16:184. doi: 10.1007/s12672.025.01958-w.
2. Lai Q, Zhao Y, Yan H, Peng H. Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL. Leuk Res 2023;135:107406. doi: 10.1016/j.leukres.2023.107406.
3. Ollila TA, Olszewski AJ. Extranodal diffuse large B cell lymphoma: Molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol 2018 Jun 21;19:38. doi: 10.1007/s11864.018.0555-8.
4. Suresh B, Asati V, Lakshmaiah KC, et al. Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India. South Asian J Cancer 2019;8:57-9. doi: 10.4103/sajc.sajc_52_18.
5. Nagakita K, Takata K, Taniguchi K, et al. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P. Pathol Int 2016;66:444-52. doi: 10.1111/pin.12439
6. Manzar GS, Cha EE, Corrigan KL, et al. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol 2024;14:1447020. doi: 10.3389/fonc.2024.144.7020.
7. Cha E, Manzar G S, Corrigan K L, et al. Outcomes and toxicities in patients with diffuse large B-cell lymphoma of the gastrointestinal tract. Int J Radiat Oncol Biol Phys 2023; 117:e460. doi: 10.3389/fonc.2024.144.7020.
8. Koch P, del Valle F, Berdel WE, et al. German Multicenter Study Group. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001;19:3861-73. doi: 10.1200/JCO.2001.19.18.3861.

9. Papaxoinis G, Papageorgiou S, Rontogianni D, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 2006;47:2140-6. doi: 10.1080/104.281.90600709226.
10. Yildirim N, Turkeli M, Akdemir MN, Simsek M, Tekin SB. Evaluation of 22 primary gastrointestinal lymphoma patients. Eurasian J Med 2019;51:53-6. doi: 10.5152/ eurasianjmed.2019.16071.
11. Liu XH, Chen G, Cao DD, et al. Comparison of clinical features of patients with or without severe gastrointestinal complications in aggressive gastrointestinal lymphomas. World J Gastrointest Oncol 2024;16:4409-23. doi: 10.4251/ wjgo.v16.i11.4409.
12. Zhang Z, Shen Y, Shen D, Ni X. Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma. BMC Gastroenterol 2012;12:77. doi: 10.1186/1471-230X-12-77.
13. Connor J, Ashton-Key M. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study. Histopathology 2007;51:697-703. doi: 10.1111/j.1365- 2559.2007.02855.x.
14. Mitchell KA, Finn WG, Owens SR. Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas. Leuk Lymphoma 2008; 49:1717-23. doi: 10.1080/104.281.90802238552.
15. Gupta V, Singh V, Bajwa R, et al. Site-specific survival of extra nodal diffuse large B-cell lymphoma and comparison with gastrointestinal diffuse large B-cell lymphoma. J Hematol 2022;11:45-54. doi: 10.14740/jh984.
16. Soyer N, Yilmaz AF, Özsan N, et al. Retrospective analysis of primary gastric diffuse largeB-cell lymphoma: a single center study from Turkey. Turk J Med Sci 2017 ;47:240-5. doi: 10.3906/sag-1510-40.